{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:45:57Z","timestamp":1787024757009,"version":"build-2736575974"},"reference-count":134,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,4,23]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Vascular complications are among the most serious manifestations of diabetes. Atherosclerosis is the main cause of reduced life quality and expectancy in diabetics, whereas diabetic nephropathy and retinopathy are the most common causes of end-stage renal disease and blindness. An effective therapeutic approach to prevent vascular complications should counteract the mechanisms of injury. Among them, the toxic effects of Advanced Glycation (AGEs) and Lipoxidation (ALEs) end-products are well-recognized contributors to these sequelae. L-carnosine (\u03b2-alanyl-Lhistidine) acts as a quencher of the AGE\/ALE precursors Reactive Carbonyl Species (RCS), which are highly reactive aldehydes derived from oxidative and non-oxidative modifications of sugars and lipids. Consistently, L-carnosine was found to be effective in several disease models in which glyco\/lipoxidation plays a central pathogenic role. Unfortunately, in humans, L-carnosine is rapidly inactivated by serum carnosinase. Therefore, the search for carnosinase-resistant derivatives of Lcarnosine represents a suitable strategy against carbonyl stress-dependent disorders, particularly diabetic vascular complications. In this review, we present and discuss available data on the efficacy of L-carnosine and its derivatives in preventing vascular complications in rodent models of diabetes and metabolic syndrome. We also discuss genetic findings providing evidence for the involvement of the carnosinase\/L-carnosine system in the risk of developing diabetic nephropathy and for preferring the use of carnosinase-resistant compounds in human disease. The availability of therapeutic strategies capable to prevent both long-term glucose toxicity, resulting from insufficient glucoselowering therapy, and lipotoxicity may help reduce the clinical and economic burden of vascular complications of diabetes and related metabolic disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867326666190711102718","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T05:14:29Z","timestamp":1562908469000},"page":"1744-1763","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes"],"prefix":"10.2174","volume":"27","author":[{"given":"Stefano","family":"Menini","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, \u201cLa Sapienza\u201d University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Iacobini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, \u201cLa Sapienza\u201d University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Blasetti","family":"Fantauzzi","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, \u201cLa Sapienza\u201d University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, \u201cLa Sapienza\u201d University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2018","unstructured":"World Health Organization. Media Centre, Diabetes: Fact Sheet. Available at: (Accessed: February 15,).2018"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cmet.2012.11.012","volume":"17","author":"Rask-Madsen C.","year":"2013","unstructured":"Rask-Madsen C.; King G.L.; Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 2013,17(1),20-33","journal-title":"Cell Metab"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00125-017-4360-x","volume":"60","author":"Forbes J.M.","year":"2017","unstructured":"Forbes J.M.; Fotheringham A.K.; Vascular complications in diabetes: old messages, new thoughts. Diabetologia 2017,60(11),2129-2138","journal-title":"Diabetologia"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Nathan D.M.","year":"1993","unstructured":"Nathan D.M.; Genuth S.; Lachin J.; Cleary P.; Crofford O.; Davis M.; Rand L.; Siebert C.; The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993,329(14),977-986","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998,352(9131),837-853","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2337\/diab.45.10.1289","volume":"45","year":"1996","unstructured":"The DCCT Research Group.The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996,45(10),1289-1298","journal-title":"Diabetes"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"Stratton I.M.","year":"2000","unstructured":"Stratton I.M.; Adler A.I.; Neil H.A.; Matthews D.R.; Manley S.E.; Cull C.A.; Hadden D.; Turner R.C.; Holman R.R.; Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000,321(7258),405-412","journal-title":"BMJ"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"Patel A.","year":"2008","unstructured":"Patel A.; MacMahon S.; Chalmers J.; Neal B.; Billot L.; Woodward M.; Marre M.; Cooper M.; Glasziou P.; Grobbee D.; Hamet P.; Harrap S.; Heller S.; Liu L.; Mancia G.; Mogensen C.E.; Pan C.; Poulter N.; Rodgers A.; Williams B.; Bompoint S.; de Galan B.E.; Joshi R.; Travert F.; Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008,358(24),2560-2572","journal-title":"N Engl J Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"Ismail-Beigi F.","year":"2010","unstructured":"Ismail-Beigi F.; Craven T.; Banerji M.A.; Basile J.; Calles J.; Cohen R.M.; Cuddihy R.; Cushman W.C.; Genuth S.; Grimm R.H.; Hamilton B.P.; Hoogwerf B.; Karl D.; Katz L.; Krikorian A.; O\u2019Connor P.; Pop-Busui R.; Schubart U.; Simmons D.; Taylor H.; Thomas A.; Weiss D.; Hramiak I.; Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010,376(9739),419-430","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"Duckworth W.","year":"2009","unstructured":"Duckworth W.; Abraira C.; Moritz T.; Reda D.; Emanuele N.; Reaven P.D.; Zieve F.J.; Marks J.; Davis S.N.; Hayward R.; Warren S.R.; Goldman S.; McCarren M.; Vitek M.E.; Henderson W.G.; Huang G.D.; Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009,360(2),129-139","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"Gerstein H.C.","year":"2008","unstructured":"Gerstein H.C.; Miller M.E.; Byington R.P.; Goff D.C.; Bigger J.T.; Buse J.B.; Cushman W.C.; Genuth S.; Ismail-Beigi F.; Grimm R.H.; Probstfield J.L.; Simons-Morton D.G.; Friedewald W.T.; Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008,358(24),2545-2559","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2337\/dc11-0996","volume":"35","author":"Seaquist E.R.","year":"2012","unstructured":"Seaquist E.R.; Miller M.E.; Bonds D.E.; Feinglos M.; Goff D.C.; Peterson K.; Senior P.; The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012,35(2),409-414","journal-title":"Diabetes Care"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1001\/jama.287.19.2563","volume":"287","year":"2002","unstructured":"Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002,287(19),2563-2569","journal-title":"JAMA"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"Nathan D.M.","year":"2005","unstructured":"Nathan D.M.; Cleary P.A.; Backlund J.Y.; Genuth S.M.; Lachin J.M.; Orchard T.J.; Raskin P.; Zinman B.; Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005,353(25),2643-2653","journal-title":"N Engl J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"Holman R.R.","year":"2008","unstructured":"Holman R.R.; Paul S.K.; Bethel M.A.; Matthews D.R.; Neil H.A.; 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008,359(15),1577-1589","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","volume":"372","author":"Hayward R.A.","year":"2015","unstructured":"Hayward R.A.; Reaven P.D.; Wiitala W.L.; Bahn G.D.; Reda D.J.; Ge L.; McCarren M.; Duckworth W.C.; Emanuele N.V.; Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015,372(23),2197-2206","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","volume":"371","author":"Zoungas S.","year":"2014","unstructured":"Zoungas S.; Chalmers J.; Neal B.; Billot L.; Li Q.; Hirakawa Y.; Arima H.; Monaghan H.; Joshi R.; Colagiuri S.; Cooper M.E.; Glasziou P.; Grobbee D.; Hamet P.; Harrap S.; Heller S.; Lisheng L.; Mancia G.; Marre M.; Matthews D.R.; Mogensen C.E.; Perkovic V.; Poulter N.; Rodgers A.; Williams B.; MacMahon S.; Patel A.; Woodward M.; Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014,371(15),1392-1406","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2337\/dc15-2283","volume":"39","year":"2016","unstructured":"ACCORD Study Group.Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes diabetes care. Diabetes Care 2016,39(5),701-708","journal-title":"Diabetes Care"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.numecd.2013.04.004","volume":"23","author":"Chilelli N.C.","year":"2013","unstructured":"Chilelli N.C.; Burlina S.; Lapolla A.; AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a \u201cglycoxidation-centric\u201d point of view. Nutr Metab Cardiovasc Dis 2013,23(10),913-919","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00125-014-3467-6","volume":"58","author":"Menini S.","year":"2015","unstructured":"Menini S.; Iacobini C.; Ricci C.; Blasetti Fantauzzi C.; Pugliese G.; Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice. Diabetologia 2015,58(4),845-853","journal-title":"Diabetologia"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2337\/dc07-1755","volume":"31","author":"Gerrits E.G.","year":"2008","unstructured":"Gerrits E.G.; Lutgers H.L.; Kleefstra N.; Graaff R.; Groenier K.H.; Smit A.J.; Gans R.O.; Bilo H.J.; Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008,31(3),517-521","journal-title":"Diabetes Care"},{"key":"ref=22","first-page":"66","volume":"154","author":"Maillard L.C.","year":"1912","unstructured":"Maillard L.C.; Action of amino acids on sugars: formation of melanoidins in a methodical way. Compt Rend 1912,154,66","journal-title":"Compt Rend"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM197608192950804","volume":"295","author":"Koenig R.J.","year":"1976","unstructured":"Koenig R.J.; Peterson C.M.; Jones R.L.; Saudek C.; Lehrman M.; Cerami A.; Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976,295(8),417-420","journal-title":"N Engl J Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1126\/science.3487117","volume":"232","author":"Brownlee M.","year":"1986","unstructured":"Brownlee M.; Vlassara H.; Kooney A.; Ulrich P.; Cerami A.; Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986,232(4758),1629-1632","journal-title":"Science"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1016\/S0021-9258(19)89188-3","volume":"261","author":"Ahmed M.U.","year":"1986","unstructured":"Ahmed M.U.; Thorpe S.R.; Baynes J.W.; Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986,261(11),4889-4894","journal-title":"J Biol Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.diabres.2004.09.004","volume":"67","author":"Ahmed N.","year":"2005","unstructured":"Ahmed N.; Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract 2005,67(1),3-21","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.48.1.1","volume":"48","author":"Baynes J.W.","year":"1999","unstructured":"Baynes J.W.; Thorpe S.R.; Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999,48(1),1-9","journal-title":"Diabetes"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1073\/pnas.94.12.6474","volume":"94","author":"Koschinsky T.","year":"1997","unstructured":"Koschinsky T.; He C.J.; Mitsuhashi T.; Bucala R.; Liu C.; Buenting C.; Heitmann K.; Vlassara H.; Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997,94(12),6474-6479","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.94.25.13915","volume":"94","author":"Cerami C.","year":"1997","unstructured":"Cerami C.; Founds H.; Nicholl I.; Mitsuhashi T.; Giordano D.; Vanpatten S.; Lee A.; Al-Abed Y.; Vlassara H.; Bucala R.; Cerami A.; Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997,94(25),13915-13920","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.1021\/bi00034a021","volume":"34","author":"Reddy S.","year":"1995","unstructured":"Reddy S.; Bichler J.; Wells-Knecht K.J.; Thorpe S.R.; Baynes J.W.; N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995,34(34),10872-10878","journal-title":"Biochemistry"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"9982","DOI":"10.1074\/jbc.271.17.9982","volume":"271","author":"Fu M.X.","year":"1996","unstructured":"Fu M.X.; Requena J.R.; Jenkins A.J.; Lyons T.J.; Baynes J.W.; Thorpe S.R.; The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996,271(17),9982-9986","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/glycob\/cwu111","volume":"25","author":"Pugliese G.","year":"2015","unstructured":"Pugliese G.; Iacobini C.; Pesce C.M.; Menini S.; Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 2015,25(2),136-150","journal-title":"Glycobiology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"F645","DOI":"10.1152\/ajprenal.00398.2004","volume":"289","author":"Bohlender J.M.","year":"2005","unstructured":"Bohlender J.M.; Franke S.; Stein G.; Wolf G.; Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005,289(4),F645-F659","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0891-5849(00)00226-4","volume":"28","author":"Uchida K.","year":"2000","unstructured":"Uchida K.; Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med 2000,28(12),1685-1696","journal-title":"Free Radic Biol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1210\/jc.2007-1817","volume":"93","author":"Goh S.Y.","year":"2008","unstructured":"Goh S.Y.; Cooper M.E.; Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008,93(4),1143-1152","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00041552-200205000-00004","volume":"11","author":"Heeringa P.","year":"2002","unstructured":"Heeringa P.; Tervaert J.W.; Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 2002,11(3),287-293","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35025203","volume":"407","author":"Lusis A.J.","year":"2000","unstructured":"Lusis A.J.; Atherosclerosis. Nature 2000,407(6801),233-241","journal-title":"Nature"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"9436","DOI":"10.1073\/pnas.91.20.9436","volume":"91","author":"Yang C.W.","year":"1994","unstructured":"Yang C.W.; Vlassara H.; Peten E.P.; He C.J.; Striker G.E.; Striker L.J.; Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994,91(20),9436-9440","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"12043","DOI":"10.1073\/pnas.89.24.12043","volume":"89","author":"Vlassara H.","year":"1992","unstructured":"Vlassara H.; Fuh H.; Makita Z.; Krungkrai S.; Cerami A.; Bucala R.; Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992,89(24),12043-12047","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/BF03401582","volume":"1","author":"Vlassara H.","year":"1995","unstructured":"Vlassara H.; Fuh H.; Donnelly T.; Cybulsky M.; Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995,1(4),447-456","journal-title":"Mol Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1096\/fj.04-2031fje","volume":"18","author":"Iacobini C.","year":"2004","unstructured":"Iacobini C.; Menini S.; Oddi G.; Ricci C.; Amadio L.; Pricci F.; Olivieri A.; Sorcini M.; Di Mario U.; Pesce C.; Pugliese G.; Galectin-3\/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB J 2004,18(14),1773-1775","journal-title":"FASEB J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00125-007-0728-7","volume":"50","author":"Menini S.","year":"2007","unstructured":"Menini S.; Iacobini C.; Ricci C.; Oddi G.; Pesce C.; Pugliese F.; Block K.; Abboud H.E.; Giorgio M.; Migliaccio E.; Pelicci P.G.; Pugliese G.; Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation. Diabetologia 2007,50(9),1997-2007","journal-title":"Diabetologia"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/eurheartj\/eht402","volume":"35","author":"Hanssen N.M.","year":"2014","unstructured":"Hanssen N.M.; Wouters K.; Huijberts M.S.; Gijbels M.J.; Sluimer J.C.; Scheijen J.L.; Heeneman S.; Biessen E.A.; Daemen M.J.; Brownlee M.; de Kleijn D.P.; Stehouwer C.D.; Pasterkamp G.; Schalkwijk C.G.; Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J 2014,35(17),1137-1146","journal-title":"Eur Heart J"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s005920070025","volume":"37","author":"Aso Y.","year":"2000","unstructured":"Aso Y.; Inukai T.; Tayama K.; Takemura Y.; Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000,37(2),87-92","journal-title":"Acta Diabetol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00125-007-0687-z","volume":"50","author":"Kilhovd B.K.","year":"2007","unstructured":"Kilhovd B.K.; Juutilainen A.; Lehto S.; R\u00f6nnemaa T.; Torjesen P.A.; Hanssen K.F.; Laakso M.; Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007,50(7),1409-1417","journal-title":"Diabetologia"},{"key":"ref=46","first-page":"1649","volume":"143","author":"Nakamura Y.","year":"1993","unstructured":"Nakamura Y.; Horii Y.; Nishino T.; Shiiki H.; Sakaguchi Y.; Kagoshima T.; Dohi K.; Makita Z.; Vlassara H.; Bucala R.; Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993,143(6),1649-1656","journal-title":"Am J Pathol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1196\/annals.1333.041","volume":"1043","author":"Schleicher E.","year":"2005","unstructured":"Schleicher E.; Weigert C.; Rohrbach H.; Nerlich A.; Bachmeier B.; Friess U.; Role of glucoxidation and lipid oxidation in the development of atherosclerosis. Ann N Y Acad Sci 2005,1043,343-354","journal-title":"Ann N Y Acad Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1097\/01.ASN.0000077413.41276.17","volume":"14","author":"Forbes J.M.","year":"2003","unstructured":"Forbes J.M.; Cooper M.E.; Oldfield M.D.; Thomas M.C.; Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003,14(8)(Suppl. 3),S254-S258","journal-title":"J Am Soc Nephrol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.1016\/j.amjhyper.2004.08.022","volume":"17","author":"Bakris G.L.","year":"2004","unstructured":"Bakris G.L.; Bank A.J.; Kass D.A.; Neutel J.M.; Preston R.A.; Oparil S.; Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004,17(12 Pt 2),23S-30S","journal-title":"Am J Hypertens"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.drudis.2006.05.016","volume":"11","author":"Reddy V.P.","year":"2006","unstructured":"Reddy V.P.; Beyaz A.; Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today 2006,11(13-14),646-654","journal-title":"Drug Discov Today"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.bjp.0707395","volume":"153","author":"Negre-Salvayre A.","year":"2008","unstructured":"Negre-Salvayre A.; Coatrieux C.; Ingueneau C.; Salvayre R.; Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008,153(1),6-20","journal-title":"Br J Pharmacol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2007.03.015","volume":"115","author":"Ellis E.M.","year":"2007","unstructured":"Ellis E.M.; Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 2007,115(1),13-24","journal-title":"Pharmacol Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/biof.5520240109","volume":"24","author":"Aldini G.","year":"2005","unstructured":"Aldini G.; Facino R.M.; Beretta G.; Carini M.; Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors 2005,24(1-4),77-87","journal-title":"Biofactors"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10545-017-0099-2","volume":"41","author":"Peters V.","year":"2018","unstructured":"Peters V.; Zschocke J.; Schmitt C.P.; Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency. J Inherit Metab Dis 2018,41(1),39-47","journal-title":"J Inherit Metab Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"9346","DOI":"10.1074\/jbc.M109.095505","volume":"285","author":"Drozak J.","year":"2010","unstructured":"Drozak J.; Veiga-da-Cunha M.; Vertommen D.; Stroobant V.; Van Schaftingen E.; Molecular identification of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1). J Biol Chem 2010,285(13),9346-9356","journal-title":"J Biol Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00726-015-2045-7","volume":"47","author":"Peters V.","year":"2015","unstructured":"Peters V.; Klessens C.Q.; Baelde H.J.; Singler B.; Veraar K.A.; Zutinic A.; Drozak J.; Zschocke J.; Schmitt C.P.; de Heer E.; Intrinsic carnosine metabolism in the human kidney. Amino Acids 2015,47(12),2541-2550","journal-title":"Amino Acids"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1016\/j.bmc.2007.06.029","volume":"15","author":"Guiotto A.","year":"2007","unstructured":"Guiotto A.; Ruzza P.; Babizhayev M.A.; Calderan A.; Malondialdehyde scavenging and aldose-derived Schiff bases\u2019 transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 2007,15(18),6158-6163","journal-title":"Bioorg Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.febslet.2007.01.082","volume":"581","author":"Rashid I.","year":"2007","unstructured":"Rashid I.; van Reyk D.M.; Davies M.J.; Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro. FEBS Lett 2007,581(5),1067-1070","journal-title":"FEBS Lett"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19375","author":"Nokin M.J.","year":"2016","unstructured":"Nokin M.J.; Durieux F.; Peixoto P.; Chiavarina B.; Peulen O.; Blomme A.; Turtoi A.; Costanza B.; Smargiasso N.; Baiwir D.; Scheijen J.L.; Schalkwijk C.G.; Leenders J.; De Tullio P.; Bianchi E.; Thiry M.; Uchida K.; Spiegel D.A.; Cochrane J.R.; Hutton C.A.; De Pauw E.; Delvenne P.; Belpomme D.; Castronovo V.; Bellahc\u00e8ne A.; Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife, 5, e193752016","journal-title":"eLife,"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1159\/000488727","volume":"46","author":"Weigand T.","year":"2018","unstructured":"Weigand T.; Singler B.; Fleming T.; Nawroth P.; Klika K.D.; Thiel C.; Baelde H.; Garbade S.F.; Wagner A.H.; Hecker M.; Yard B.A.; Amberger A.; Zschocke J.; Schmitt C.P.; Peters V.; Carnosine catalyzes the formation of the oligo\/polymeric products of methylglyoxal. Cell Physiol Biochem 2018,46(2),713-726","journal-title":"Cell Physiol Biochem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1742-7843.2005.pto_03.x","volume":"96","author":"Mozdzan M.","year":"2005","unstructured":"Mozdzan M.; Szemraj J.; Rysz J.; Nowak D.; Antioxidant properties of carnosine re-evaluated with oxidizing systems involving iron and copper ions. Basic Clin Pharmacol Toxicol 2005,96(5),352-360","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=62","first-page":"766","volume":"65","author":"Decker E.A.","year":"2000","unstructured":"Decker E.A.; Livisay S.A.; Zhou S.; A re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc) 2000,65(7),766-770","journal-title":"Biochemistry (Mosc)"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.colsurfb.2008.06.012","volume":"66","author":"Velez S.","year":"2008","unstructured":"Velez S.; Nair N.G.; Reddy V.P.; Transition metal ion binding studies of carnosine and histidine: biologically relevant antioxidants. Colloids Surf B Biointerfaces 2008,66(2),291-294","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1111\/j.1476-5381.2012.01834.x","volume":"166","author":"Menini S.","year":"2012","unstructured":"Menini S.; Iacobini C.; Ricci C.; Scipioni A.; Blasetti Fantauzzi C.; Giaccari A.; Salomone E.; Canevotti R.; Lapolla A.; Orioli M.; Aldini G.; Pugliese G.; D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol 2012,166(4),1344-1356","journal-title":"Br J Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bph.14070","volume":"175","author":"Iacobini C.","year":"2018","unstructured":"Iacobini C.; Menini S.; Blasetti Fantauzzi C.; Pesce C.M.; Giaccari A.; Salomone E.; Lapolla A.; Orioli M.; Aldini G.; Pugliese G.; FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db\/db mice. Br J Pharmacol 2018,175(1),53-66","journal-title":"Br J Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1021\/bi060348s","volume":"45","author":"Pattison D.I.","year":"2006","unstructured":"Pattison D.I.; Davies M.J.; Evidence for rapid inter- and intramolecular chlorine transfer reactions of histamine and carnosine chloramines: implications for the prevention of hypochlorous-acid-mediated damage. Biochemistry 2006,45(26),8152-8162","journal-title":"Biochemistry"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1152\/physrev.00039.2012","volume":"93","author":"Boldyrev A.A.","year":"2013","unstructured":"Boldyrev A.A.; Aldini G.; Derave W.; Physiology and pathophysiology of carnosine. Physiol Rev 2013,93(4),1803-1845","journal-title":"Physiol Rev"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cbpc.2003.10.008","volume":"137","author":"Boldyrev A.","year":"2004","unstructured":"Boldyrev A.; Bulygina E.; Leinsoo T.; Petrushanko I.; Tsubone S.; Abe H.; Protection of neuronal cells against reactive oxygen species by carnosine and related compounds. Comp Biochem Physiol B Biochem Mol Biol 2004,137(1),81-88","journal-title":"Comp Biochem Physiol B Biochem Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.lfs.2004.05.002","volume":"75","author":"Hobart L.J.","year":"2004","unstructured":"Hobart L.J.; Seibel I.; Yeargans G.S.; Seidler N.W.; Anti-crosslinking properties of carnosine: significance of histidine. Life Sci 2004,75(11),1379-1389","journal-title":"Life Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gdata.2016.09.004","volume":"10","author":"Wada N.","year":"2016","unstructured":"Wada N.; Yamanaka S.; Shibato J.; Rakwal R.; Hirako S.; Iizuka Y.; Kim H.; Matsumoto A.; Kimura A.; Takenoya F.; Yasunaga G.; Shioda S.; Behavioral and omics analyses study on potential involvement of dipeptide balenine through supplementation in diet of senescence-accelerated mouse prone 8. Genom Data 2016,10,38-50","journal-title":"Genom Data"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"9174","DOI":"10.1021\/ac7016184","volume":"79","author":"Orioli M.","year":"2007","unstructured":"Orioli M.; Aldini G.; Benfatto M.C.; Facino R.M.; Carini M.; HNE Michael adducts to histidine and histidine-containing peptides as biomarkers of lipid-derived carbonyl stress in urines: LC-MS\/MS profiling in Zucker obese rats. Anal Chem 2007,79(23),9174-9184","journal-title":"Anal Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/cmdc.200600075","volume":"1","author":"Aldini G.","year":"2006","unstructured":"Aldini G.; Dalle-Donne I.; Colombo R.; Maffei Facino R.; Milzani A.; Carini M.; Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. ChemMedChem 2006,1(10),1045-1058","journal-title":"ChemMedChem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1196\/annals.1356.013","volume":"1057","author":"Boldyrev A.A.","year":"2005","unstructured":"Boldyrev A.A.; Protection of proteins from oxidative stress: a new illusion or a novel strategy? Ann N Y Acad Sci 2005,1057(1),193-205","journal-title":"Ann N Y Acad Sci"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.maturitas.2016.06.002","volume":"93","author":"Hipkiss A.R.","year":"2016","unstructured":"Hipkiss A.R.; Baye E.; de Courten B.; Carnosine and the processes of ageing. Maturitas 2016,93,28-33","journal-title":"Maturitas"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1016\/j.lfs.2005.09.054","volume":"78","author":"Babizhayev M.A.","year":"2006","unstructured":"Babizhayev M.A.; Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci 2006,78(20),2343-2357","journal-title":"Life Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1124\/jpet.106.110122","volume":"319","author":"Kurata H.","year":"2006","unstructured":"Kurata H.; Fujii T.; Tsutsui H.; Katayama T.; Ohkita M.; Takaoka M.; Tsuruoka N.; Kiso Y.; Ohno Y.; Fujisawa Y.; Shokoji T.; Nishiyama A.; Abe Y.; Matsumura Y.; Renoprotective effects of l-carnosine on ischemia\/reperfusion-induced renal injury in rats. J Pharmacol Exp Ther 2006,319(2),640-647","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=77","first-page":"BR73","volume":"13","author":"Soliman K.M.","year":"2007","unstructured":"Soliman K.M.; Abdul-Hamid M.; Othman A.I.; Effect of carnosine on gentamicin-induced nephrotoxicity. Med Sci Monit 2007,13(3),BR73-BR83","journal-title":"Med Sci Monit"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"L1095","DOI":"10.1152\/ajplung.00283.2006","volume":"292","author":"Cuzzocrea S.","year":"2007","unstructured":"Cuzzocrea S.; Genovese T.; Failla M.; Vecchio G.; Fruciano M.; Mazzon E.; Di Paola R.; Mui\u00e0 C.; La Rosa C.; Crimi N.; Rizzarelli E.; Vancheri C.; Protective effect of orally administered carnosine on bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2007,292(5),L1095-L1104","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1161\/STROKEAHA.107.488502","volume":"38","author":"Rajanikant G.K.","year":"2007","unstructured":"Rajanikant G.K.; Zemke D.; Senut M.C.; Frenkel M.B.; Chen A.F.; Gupta R.; Majid A.; Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. Stroke 2007,38(11),3023-3031","journal-title":"Stroke"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1471-4159.2006.04412.x","volume":"101","author":"Tang S.C.","year":"2007","unstructured":"Tang S.C.; Arumugam T.V.; Cutler R.G.; Jo D.G.; Magnus T.; Chan S.L.; Mughal M.R.; Telljohann R.S.; Nassar M.; Ouyang X.; Calderan A.; Ruzza P.; Guiotto A.; Mattson M.P.; Neuroprotective actions of a histidine analogue in models of ischemic stroke. J Neurochem 2007,101(3),729-736","journal-title":"J Neurochem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.2337\/diabetes.54.8.2320","volume":"54","author":"Janssen B.","year":"2005","unstructured":"Janssen B.; Hohenadel D.; Brinkkoetter P.; Peters V.; Rind N.; Fischer C.; Rychlik I.; Cerna M.; Romzova M.; de Heer E.; Baelde H.; Bakker S.J.; Zirie M.; Rondeau E.; Mathieson P.; Saleem M.A.; Meyer J.; K\u00f6ppel H.; Sauerhoefer S.; Bartram C.R.; Nawroth P.; Hammes H.P.; Yard B.A.; Zschocke J.; van der Woude F.J.; Carnosine as a protective factor in diabetic nephropathy: association with a leucine repeat of the carnosinase gene CNDP1. Diabetes 2005,54(8),2320-2327","journal-title":"Diabetes"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"c26","DOI":"10.1159\/000106509","volume":"107","author":"Alhamdani M.S.","year":"2007","unstructured":"Alhamdani M.S.; Al-Kassir A.H.; Abbas F.K.; Jaleel N.A.; Al-Taee M.F.; Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells. Nephron Clin Pract 2007,107(1),c26-c34","journal-title":"Nephron Clin Pract"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bcp.2006.11.007","volume":"73","author":"Shen Y.","year":"2007","unstructured":"Shen Y.; Hu W.W.; Fan Y.Y.; Dai H.B.; Fu Q.L.; Wei E.Q.; Luo J.H.; Chen Z.; Carnosine protects against NMDA-induced neurotoxicity in differentiated rat PC12 cells through carnosine-histidine-histamine pathway and H(1)\/H(3) receptors. Biochem Pharmacol 2007,73(5),709-717","journal-title":"Biochem Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11064-005-6874-8","volume":"30","author":"Calabrese V.","year":"2005","unstructured":"Calabrese V.; Colombrita C.; Guagliano E.; Sapienza M.; Ravagna A.; Cardile V.; Scapagnini G.; Santoro A.M.; Mangiameli A.; Butterfield D.A.; Giuffrida Stella A.M.; Rizzarelli E.; Protective effect of carnosine during nitrosative stress in astroglial cell cultures. Neurochem Res 2005,30(6-7),797-807","journal-title":"Neurochem Res"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.regpep.2008.12.004","volume":"154","author":"Jia H.","year":"2009","unstructured":"Jia H.; Qi X.; Fang S.; Jin Y.; Han X.; Wang Y.; Wang A.; Zhou H.; Carnosine inhibits high glucose-induced mesangial cell proliferation through mediating cell cycle progression. Regul Pept 2009,154(1-3),69-76","journal-title":"Regul Pept"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1093\/ndt\/gfr324","volume":"26","author":"K\u00f6ppel H.","year":"2011","unstructured":"K\u00f6ppel H.; Riedl E.; Braunagel M.; Sauerhoefer S.; Ehnert S.; Godoy P.; Sternik P.; Dooley S.; Yard B.A.; L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-\u03b2 production and signalling. Nephrol Dial Transplant 2011,26(12),3852-3858","journal-title":"Nephrol Dial Transplant"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"44492","DOI":"10.1038\/srep44492","volume":"7","author":"Albrecht T.","year":"2017","unstructured":"Albrecht T.; Schilperoort M.; Zhang S.; Braun J.D.; Qiu J.; Rodriguez A.; Pastene D.O.; Kr\u00e4mer B.K.; K\u00f6ppel H.; Baelde H.; de Heer E.; Anna Altomare A.; Regazzoni L.; Denisi A.; Aldini G.; van den Born J.; Yard B.A.; Hauske S.J.; Carnosine attenuates the development of both type 2 diabetes and diabetic nephropathy in BTBR ob\/ob mice. Sci Rep 2017,7,44492","journal-title":"Sci Rep"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1681\/ASN.2009121290","volume":"21","author":"Hudkins K.L.","year":"2010","unstructured":"Hudkins K.L.; Pichaiwong W.; Wietecha T.; Kowalewska J.; Banas M.C.; Spencer M.W.; M\u00fchlfeld A.; Koelling M.; Pippin J.W.; Shankland S.J.; Askari B.; Rabaglia M.E.; Keller M.P.; Attie A.D.; Alpers C.E.; BTBR Ob\/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 2010,21(9),1533-1542","journal-title":"J Am Soc Nephrol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/j.1582-4934.2010.01101.x","volume":"15","author":"Aldini G.","year":"2011","unstructured":"Aldini G.; Orioli M.; Rossoni G.; Savi F.; Braidotti P.; Vistoli G.; Yeum K.J.; Negrisoli G.; Carini M.; The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. J Cell Mol Med 2011,15(6),1339-1354","journal-title":"J Cell Mol Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1999.tb07782.x","volume":"892","author":"Hansen B.C.","year":"1999","unstructured":"Hansen B.C.; The metabolic syndrome X. Ann N Y Acad Sci 1999,892,1-24","journal-title":"Ann N Y Acad Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s00726-011-1046-4","volume":"42","author":"Peters V.","year":"2012","unstructured":"Peters V.; Schmitt C.P.; Zschocke J.; Gross M.L.; Brismar K.; Forsberg E.; Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids 2012,42(6),2411-2416","journal-title":"Amino Acids"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"F1138","DOI":"10.1152\/ajprenal.00315.2002","volume":"284","author":"Sharma K.","year":"2003","unstructured":"Sharma K.; McCue P.; Dunn S.R.; Diabetic kidney disease in the db\/db mouse. Am J Physiol Renal Physiol 2003,284(6),F1138-F1144","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.2337\/diabetes.51.10.3107","volume":"51","author":"Hammes H.P.","year":"2002","unstructured":"Hammes H.P.; Lin J.; Renner O.; Shani M.; Lundqvist A.; Betsholtz C.; Brownlee M.; Deutsch U.; Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002,51(10),3107-3112","journal-title":"Diabetes"},{"key":"ref=94","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/106594","volume":"2013","author":"Lai A.K.","year":"2013","unstructured":"Lai A.K.; Lo A.C.; Animal models of diabetic retinopathy: summary and comparison. J Diabetes Res 2013,2013","journal-title":"J Diabetes Res"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000331721","volume":"28","author":"Pfister F.","year":"2011","unstructured":"Pfister F.; Riedl E.; Wang Q.; vom Hagen F.; Deinzer M.; Harmsen M.C.; Molema G.; Yard B.; Feng Y.; Hammes H.P.; Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell Physiol Biochem 2011,28(1),125-136","journal-title":"Cell Physiol Biochem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jdiacomp.2008.04.001","volume":"23","author":"Gul A.","year":"2009","unstructured":"Gul A.; Rahman M.A.; Salim A.; Simjee S.U.; Advanced glycation end products in senile diabetic and nondiabetic patients with cataract. J Diabetes Complications 2009,23(5),343-348","journal-title":"J Diabetes Complications"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s11892-014-0541-x","volume":"14","author":"Stirban A.","year":"2014","unstructured":"Stirban A.; Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep 2014,14(11),541","journal-title":"Curr Diab Rep"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.freeradbiomed.2011.01.037","volume":"50","author":"Lupachyk S.","year":"2011","unstructured":"Lupachyk S.; Shevalye H.; Maksimchyk Y.; Drel V.R.; Obrosova I.G.; PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: correlation with peripheral nerve function. Free Radic Biol Med 2011,50(10),1400-1409","journal-title":"Free Radic Biol Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3109\/10715762.2010.498478","volume":"44","author":"Negre-Salvayre A.","year":"2010","unstructured":"Negre-Salvayre A.; Auge N.; Ayala V.; Basaga H.; Boada J.; Brenke R.; Chapple S.; Cohen G.; Feher J.; Grune T.; Lengyel G.; Mann G.E.; Pamplona R.; Poli G.; Portero-Otin M.; Riahi Y.; Salvayre R.; Sasson S.; Serrano J.; Shamni O.; Siems W.; Siow R.C.M.; Wiswedel I.; Zarkovic K.; Zarkovic N.; Pathological aspects of lipid peroxidation. Free Radic Res 2010,44(10),1125-1171","journal-title":"Free Radic Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejphar.2008.10.002","volume":"600","author":"Kamei J.","year":"2008","unstructured":"Kamei J.; Ohsawa M.; Miyata S.; Tanaka S.; Preventive effect of L-carnosine on changes in the thermal nociceptive threshold in streptozotocin-induced diabetic mice. Eur J Pharmacol 2008,600(1-3),83-86","journal-title":"Eur J Pharmacol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jdiacomp.2015.12.018","volume":"30","author":"Domingueti C.P.","year":"2016","unstructured":"Domingueti C.P.; Dusse L.M.; Carvalho Md.; de Sousa L.P.; Gomes K.B.; Fernandes A.P.; Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications 2016,30(4),738-745","journal-title":"J Diabetes Complications"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.amjmed.2007.07.003","volume":"120","author":"Boyle P.J.","year":"2007","unstructured":"Boyle P.J.; Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007,120(1),S12-S17","journal-title":"Am J Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1046\/j.1523-1755.2000.07615.x","volume":"76","author":"Miyata T.","year":"2000","unstructured":"Miyata T.; Kurokawa K.; van Ypersele de Strihou C.; Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int Suppl 2000,76,S120-S125","journal-title":"Kidney Int Suppl"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejphar.2005.02.010","volume":"513","author":"Lee Y.T.","year":"2005","unstructured":"Lee Y.T.; Hsu C.C.; Lin M.H.; Liu K.S.; Yin M.C.; Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. Eur J Pharmacol 2005,513(1-2),145-150","journal-title":"Eur J Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.5713\/ajas.14.0604","volume":"28","author":"Bao Y.","year":"2015","unstructured":"Bao Y.; Gao C.; Hao W.; Ji C.; Zhao L.; Zhang J.; Liu T.; Ma Q.; Effects of dietary l-carnosine and alpha-lipoic acid on growth performance, blood thyroid hormones and lipid profiles in finishing pigs. Asian-Australas J Anim Sci 2015,28(10),1465-1470","journal-title":"Asian-Australas J Anim Sci"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejphar.2010.12.001","volume":"653","author":"Mong M.C.","year":"2011","unstructured":"Mong M.C.; Chao C.Y.; Yin M.C.; Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. Eur J Pharmacol 2011,653(1-3),82-88","journal-title":"Eur J Pharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejphar.2017.05.010","volume":"816","author":"Emini Veseli B.","year":"2017","unstructured":"Emini Veseli B.; Perrotta P.; De Meyer G.R.A.; Roth L.; Van der Donckt C.; Martinet W.; De Meyer G.R.Y.; Animal models of atherosclerosis. Eur J Pharmacol 2017,816,3-13","journal-title":"Eur J Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.atherosclerosis.2013.11.068","volume":"232","author":"Brown B.E.","year":"2014","unstructured":"Brown B.E.; Kim C.H.; Torpy F.R.; Bursill C.A.; McRobb L.S.; Heather A.K.; Davies M.J.; van Reyk D.M.; Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E(-\/-) mice. Atherosclerosis 2014,232(2),403-409","journal-title":"Atherosclerosis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.2337\/db07-0177","volume":"56","author":"Sauerh\u00f6fer S.","year":"2007","unstructured":"Sauerh\u00f6fer S.; Yuan G.; Braun G.S.; Deinzer M.; Neumaier M.; Gretz N.; Floege J.; Kriz W.; van der Woude F.; Moeller M.J.; L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. Diabetes 2007,56(10),2425-2432","journal-title":"Diabetes"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/ndt\/gfl717","volume":"22","author":"Freedman B.I.","year":"2007","unstructured":"Freedman B.I.; Hicks P.J.; Sale M.M.; Pierson E.D.; Langefeld C.D.; Rich S.S.; Xu J.; McDonough C.; Janssen B.; Yard B.A.; van der Woude F.J.; Bowden D.W.; A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol Dial Transplant 2007,22(4),1131-1135","journal-title":"Nephrol Dial Transplant"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1007\/s00125-010-1863-0","volume":"53","author":"Alkhalaf A.","year":"2010","unstructured":"Alkhalaf A.; Bakker S.J.; Bilo H.J.; Gans R.O.; Navis G.J.; Postmus D.; Forsblom C.; Groop P.H.; Vionnet N.; Hadjadj S.; Marre M.; Parving H.H.; Rossing P.; Tarnow L.; A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia 2010,53(12),2562-2568","journal-title":"Diabetologia"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00125-011-2178-5","volume":"54","author":"Ahluwalia T.S.","year":"2011","unstructured":"Ahluwalia T.S.; Lindholm E.; Groop L.C.; Common variants in CNDP1 and CNDP2, and risk of nephropathy in type 2 diabetes. Diabetologia 2011,54(9),2295-2302","journal-title":"Diabetologia"},{"key":"ref=113","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9506730","volume":"2017","author":"Albrecht T.","year":"2017","unstructured":"Albrecht T.; Zhang S.; Braun J.D.; Xia L.; Rodriquez A.; Qiu J.; Peters V.; Schmitt C.P.; van den Born J.; Bakker S.J.L.; Lammert A.; K\u00f6ppel H.; Schnuelle P.; Kr\u00e4mer B.K.; Yard B.A.; Hauske S.J.; The CNDP1 (CTG) Polymorphism is associated with biopsy-proven diabetic nephropathy, time on hemodialysis, and diabetes duration. J Diabetes Res 2017,2017","journal-title":"J Diabetes Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ejmech.2007.03.038","volume":"43","author":"Bellia F.","year":"2007","unstructured":"Bellia F.; Amorini A.M.; La Mendola D.; Vecchio G.; Tavazzi B.; Giardina B.; Di Pietro V.; Lazzarino G.; Rizzarelli E.; New glycosidic derivatives of histidine-containing dipeptides with antioxidant properties and resistant to carnosinase activity. Diabetologia, 2007, 53(12), 2562-2568. Eur J Med Chem 2007,43(2),373-380","journal-title":"Eur J Med Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00726-012-1224-z","volume":"43","author":"Vistoli G.","year":"2012","unstructured":"Vistoli G.; Carini M.; Aldini G.; Transforming dietary peptides in promising lead compounds: the case of bioavailable carnosine analogs. Amino Acids 2012,43(1),111-126","journal-title":"Amino Acids"},{"key":"ref=116","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092751","volume":"19","author":"Peters V.","year":"2018","unstructured":"Peters V.; Calabrese V.; Forsberg E.; Volk N.; Fleming T.; Baelde H.; Weigand T.; Thiel C.; Trovato A.; Scuto M.; Modafferi S.; Schmitt C.P.; Protective actions of anserine under diabetic conditions. Int J Mol Sci 2018,19(9)","journal-title":"Int J Mol Sci"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s00726-015-2024-z","volume":"47","author":"Peters V.","year":"2015","unstructured":"Peters V.; Lanthaler B.; Amberger A.; Fleming T.; Forsberg E.; Hecker M.; Wagner A.H.; Yue W.W.; Hoffmann G.F.; Nawroth P.; Zschocke J.; Schmitt C.P.; Carnosine metabolism in diabetes is altered by reactive metabolites. Amino Acids 2015,47(11),2367-2376","journal-title":"Amino Acids"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/cmdc.200800433","volume":"4","author":"Vistoli G.","year":"2009","unstructured":"Vistoli G.; Orioli M.; Pedretti A.; Regazzoni L.; Canevotti R.; Negrisoli G.; Carini M.; Aldini G.; Design, synthesis, and evaluation of carnosine derivatives as selective and efficient sequestering agents of cytotoxic reactive carbonyl species. ChemMedChem 2009,4(6),967-975","journal-title":"ChemMedChem"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/cmdc.201100042","volume":"6","author":"Orioli M.","year":"2011","unstructured":"Orioli M.; Vistoli G.; Regazzoni L.; Pedretti A.; Lapolla A.; Rossoni G.; Canevotti R.; Gamberoni L.; Previtali M.; Carini M.; Aldini G.; Design, synthesis, ADME properties, and pharmacological activities of \u03b2-alanyl-D-histidine (D-carnosine) prodrugs with improved bioavailability. ChemMedChem 2011,6(7),1269-1282","journal-title":"ChemMedChem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","volume":"71","author":"Plump A.S.","year":"1992","unstructured":"Plump A.S.; Smith J.D.; Hayek T.; Aalto-Set\u00e4l\u00e4 K.; Walsh A.; Verstuyft J.G.; Rubin E.M.; Breslow J.L.; Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992,71(2),343-353","journal-title":"Cell"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/01.LAB.0000022222.03120.D4","volume":"82","author":"Wen M.","year":"2002","unstructured":"Wen M.; Segerer S.; Dantas M.; Brown P.A.; Hudkins K.L.; Goodpaster T.; Kirk E.; LeBoeuf R.C.; Alpers C.E.; Renal injury in apolipoprotein E-deficient mice. Lab Invest 2002,82(8),999-1006","journal-title":"Lab Invest"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1681\/ASN.2010080798","volume":"22","author":"Anders H.J.","year":"2011","unstructured":"Anders H.J.; Muruve D.A.; The inflammasomes in kidney disease. J Am Soc Nephrol 2011,22(6),1007-1018","journal-title":"J Am Soc Nephrol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/path.4237","volume":"231","author":"Solini A.","year":"2013","unstructured":"Solini A.; Menini S.; Rossi C.; Ricci C.; Santini E.; Blasetti Fantauzzi C.; Iacobini C.; Pugliese G.; The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol 2013,231(3),342-353","journal-title":"J Pathol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMe0807625","volume":"359","author":"Chalmers J.","year":"2008","unstructured":"Chalmers J.; Cooper M.E.; UKPDS and the legacy effect. N Engl J Med 2008,359(15),1618-1620","journal-title":"N Engl J Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.peptides.2016.10.008","volume":"86","author":"Ahshin-Majd S.","year":"2016","unstructured":"Ahshin-Majd S.; Zamani S.; Kiamari T.; Kiasalari Z.; Baluchnejadmojarad T.; Roghani M.; Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms. Peptides 2016,86,102-111","journal-title":"Peptides"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/oby.21434","volume":"24","author":"de Courten B.","year":"2016","unstructured":"de Courten B.; Jakubova M.; de Courten M.P.; Kukurova I.J.; Vallova S.; Krumpolec P.; Valkovic L.; Kurdiova T.; Garzon D.; Barbaresi S.; Teede H.J.; Derave W.; Krssak M.; Aldini G.; Ukropec J.; Ukropcova B.; Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. Obesity (Silver Spring) 2016,24(5),1027-1034","journal-title":"Obesity (Silver Spring)"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1530\/JOE-14-0571","volume":"225","author":"Forsberg E.A.","year":"2015","unstructured":"Forsberg E.A.; Botusan I.R.; Wang J.; Peters V.; Ansurudeen I.; Brismar K.; Catrina S.B.; Carnosine decreases IGFBP1 production in db\/db mice through suppression of HIF-1. J Endocrinol 2015,225(3),159-167","journal-title":"J Endocrinol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"27224","DOI":"10.1038\/srep27224","volume":"6","author":"Regazzoni L.","year":"2016","unstructured":"Regazzoni L.; de Courten B.; Garzon D.; Altomare A.; Marinello C.; Jakubova M.; Vallova S.; Krumpolec P.; Carini M.; Ukropec J.; Ukropcova B.; Aldini G.; A carnosine intervention study in overweight human volunteers: bioavailability and reactive carbonyl species sequestering effect. Sci Rep 2016,6,27224","journal-title":"Sci Rep"},{"key":"ref=129","doi-asserted-by":"publisher","DOI":"10.3390\/nu10091258","volume":"10","author":"Baye E.","year":"2018","unstructured":"Baye E.; Ukropec J.; de Courten M.P.J.; Mousa A.; Kurdiova T.; Johnson J.; Wilson K.; Plebanski M.; Aldini G.; Ukropcova B.; de Courten B.; Carnosine supplementation improves serum resistin concentrations in overweight or obese otherwise healthy adults: a pilot randomized trial. Nutrients 2018,10(9)","journal-title":"Nutrients"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00726-018-2623-6","volume":"51","author":"Baye E.","year":"2018","unstructured":"Baye E.; Ukropec J.; de Courten M.P.J.; Kurdiova T.; Krumpolec P.; Fern\u00e1ndez-Real J.M.; Aldini G.; Ukropcova B.; de Courten B.; Carnosine supplementation reduces plasma soluble transferrin receptor in healthy overweight or obese individuals: a pilot randomised trial. Amino Acids 2018,51(1),73-81","journal-title":"Amino Acids"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"17458","DOI":"10.1038\/s41598-017-17577-7","volume":"7","author":"Baye E.","year":"2017","unstructured":"Baye E.; Ukropec J.; de Courten M.P.; Vallova S.; Krumpolec P.; Kurdiova T.; Aldini G.; Ukropcova B.; de Courten B.; Effect of carnosine supplementation on the plasma lipidome in overweight and obese adults: a pilot randomised controlled trial. Sci Rep 2017,7(1),17458","journal-title":"Sci Rep"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.1172\/JCI94307","volume":"128","author":"Anderson E.J.","year":"2018","unstructured":"Anderson E.J.; Vistoli G.; Katunga L.A.; Funai K.; Regazzoni L.; Monroe T.B.; Gilardoni E.; Cannizzaro L.; Colzani M.; De Maddis D.; Rossoni G.; Canevotti R.; Gagliardi S.; Carini M.; Aldini G.; A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress. J Clin Invest 2018,128(12),5280-5293","journal-title":"J Clin Invest"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017691","volume":"7","author":"Baye E.","year":"2017","unstructured":"Baye E.; Menon K.; de Courten M.P.; Earnest A.; Cameron J.; de Courten B.; Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open 2017,7(9)","journal-title":"BMJ Open"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/pedi.12564","volume":"19","author":"Elbarbary N.S.","year":"2018","unstructured":"Elbarbary N.S.; Ismail E.A.R.; El-Naggar A.R.; Hamouda M.H.; El-Hamamsy M.; The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial. Pediatr Diabetes 2018,19(3),470-477","journal-title":"Pediatr Diabetes"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/173412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T23:35:25Z","timestamp":1610408125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/173412\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":134,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,4,23]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190711102718","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}